Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With Human Immunodeficiency Virus: Outcomes in Real-world Setting With and Without Tenofovir Resistance

undefined; Alain Makinson; Firouze Bani-Sadr; Romain Palich; Brigitte Montès; Anne Maillard; Claudine Duvivier; David Rey; Agathe Becker; Laurent Hocqueloux; François Raffi; C Chirouze; K Bouiller; F Bozon; A S Brunel; L Hustache-Mathieu; J Lagoutte; Q Lepiller; S Marty-Quinternet; L Pépin-Puget; B Rosolen; N Tissot; C Lebreton; L Bohard; S Jaffuel; S Ansart; Y Quintric; S Rezig; L Quaesaet; P Gazeau; C Jacomet; N Mrozek; C Theis; M Vidal; C Richaud; F Anglade; V Corbin; A Benelhadj; undefined Djelloul; A Zaghdoudi; C Aumeran; O Baud; E Goncalves; D Mazzocolin; A Mirand; A Brebion; C Henquell; I Lamaury; G Baronnet; F Bissuel; F Boulard; A Chéret; J Coussement; E Curlier; T Dequidt; C Desfontaines; E Duvallon; I Fabre; C Herrmann-Storck; C Lahuna; C Loraux; S Markowicz; M Marquet; R Ouissa; S Peugny; L Pradat-Paz; M C Receveur; J Reltien; K Samar; B Tressieres; V Walter; D Merrien; O Bollangier; D Boucher; T Guimard; L Laine; S Leautez; M Morrier; P Perré; M Roncato-Saberan; X Pouget-Abadie; C Chapuzet; A Thomas; J F Faucher; A Cypierre; S Ducroix-Roubertou; H Durox; C Genet-Villeger; J Pascual; P Pinet; C Codde; S Rogez; J B Woillard; C Benoist; D Alfaiate; A Becker; M Godinot; F Ader; E Braun; C Brochier; F Brunel-Dalmas; P Chiarello; A Conrad; S Degroodt; P Fascia; T Ferry; V Gueripel; V Icard; J Izard; C Javaux; H Lardot; J Lippmann; D Makhloufi; Y Merad; T Perpoint; S Roux; S Sahyouni; M Simon; M A Trabaud; C Triffault-Fillit; F Valour; A S Batalla; L Van den Bogaart; A Ménard; Y Belkhir; P Colson; C Dhiver; M Martin-Degioanni; A Motte; C Toméi; M Million; N De Palmas; M Champeaux; I Ravaux; S Brégigeon; O Zaegel-Faucher; H Laroche; M Dos Santos; M J Ducassou; A Ivanova; I Jaquet; V Obry-Roguet; M Orticoni; E Ressiot; A S Ritleng; S Benkouiten; A Cabié; S Abel; O Cabras; L Cuzin; G Dos Santos; L Facelina; L Fagour; L de Ghellinck; K Guitteaud; E Louis-Michel; F Quenard; S Pierre-François; P Richard; A Schapira; C Robert; Z Cavalli; L Bucy; A Fournier; A Makinson; M Bistoquet; E Delaporte; V Le Moing; J Lejeune; N Meftah; C Merle de Boever; B Montes; L Perez; N Pansu; J Reynes; E Tuaillon; B Lefèvre; B Lefèvre; M André; S Bevilacqua; L Boyer; M P Grandin; A Charmillon; M Delestan; E Frentiu; F Goehringer; S Hénard; E Jeanmaire; C Rabaud; L Lalevée; C Allavena; E André-Garnier; A Asquier-Khati; V Bellon; E Billaud; C Biron; B Bonnet; S Bouchez; D Boutoille; C Brunet-Cartier; M Cavellec; L Collias; C Deschanvres; T Drumel; B J Gaborit; M Gregoire; T Jovelin; M Lefebvre; R Lecomte; R Mahot; C Mear-Passard; P Morineau; C Moyon; E Paredes; G Querne; F Raffi; V Reliquet; A Soria; P Pugliese; S Bréaud; M Buscot; M Carles; D Chirio; J Courjon; E Cua; P Dellamonica; E Demonchy; A De Monte; J Durant; S Ferrando; A Naqvi; I Perbost; C Pradier; B Prouvost-Keller; K Risso; I Touitou; A Viot; S Wehrlen-Pugliese; S Sunder; V Goudet; A Dos Santos; V Rzepecki; L Hocqueloux; V Avettand-Fènoël; G Béraud; C Gubavu; V Legros; G Mchantaf; C Mille; T Prazuck; A Salmon-Rousseau; A Sève; L Vitry d’Aubigny; C Goujard; A Castro-Gordon; P David-Chevallier; V Godard; Y Quertainmont; E Teicher; M Royer; S Jaureguiberry; L Escaut; M Cresta; B Henry; E Oliosi; C Couzigou; O Derradji; R Collarino; Y Liotier; M Merad; E Zamparini; J Bottero; V Joly; C Charpentier; D Descamps; M Digumber; A Gervais; J Ghosn; Z Julia; R Landman; S Lariven; S Le Gac; F Louni; N Peiffer-Smadja; G Peytavin; C Rioux; Y Yazdanpanah; L Deconinck; C Duvivier; K Amazzough; G Benabdelmoumen; P Bossi; G Cessot; C Charlier; P H Consigny; C De La Porte Des Vaux; M Garzaro; E Gomes-Pires; P Hochedez; O Itani; K Jidar; E Lafont; F Lanternier; O Lortholary; C Louisin; J Lourenco; C Melenotte; O Pacoud; P Parize; F Runyo; C Rouzaud; F Taieb; J Zeggagh; R Palich; M A Valantin; C Katlama; L Schneider; S Seang; R Tubiana; A Faycal; S Saliba; M Favier; C Aubron; R Agher; Y Dudoit; N Hamani; N Qatib; A Chermak; M Chansombat; G Osseni; D Beniken; N Hall; P Perfezou; J C Duthe; F B Drevillon; J P Talarmin; L Khatchatourian; P Petitgas; F Bani-Sadr; V Brodard; M Hentzien; I Kmiec; D Lambert; D Lebrun; M Moutel; A Brunet; H Marty; Y N’Guyen; C Arvieux; M Baldeyrou; F Benezit; M Cailleaux; J M Chapplain; M Dupont; J C Duthé; S Ismaël; T Jovelin; A Lebot; F Lemaitre; D Luque-Paz; A Maillard; C Morlat; S Patrat-Delon; L Picard; M Poisson-Vannier; C Pronier; M Revest; M Sebillotte; P Tattevin; J Vivent; A Gagneux-Brunon; E Botelho-Nevers; A Frésard; A Pouvaret; F Saunier; V Ronat; A Ursenbach; C Cheneau; C Bernard-Henry; S Fafi-Kremer; P Fischer; P Gantner; C Mélounou; P Klee; Y Hansmann; N Lefebvre; Y Ruch; F Danion; B Hoellinger; T Lemmet; V Gerber; J M Schevin; A Fuchs; C Le Hyaric; D Rey; P Delobel; M Alvarez; N Biezunski; X Boumaza; A Chan Sui Ko; N Collercandy; A Debard; C Delpierre; P Gandia; C Garnier; R Gueneau; L Lelièvre; G Martin-Blondel; C Rastoll; S Raymond; C Vellas; O Robineau; E Aïssi; I Alcaraz; E Alidjinou; V Baclet; A Boucher; V Derdour; B Lafon-Desmurs; A Meybeck; M Pradier; M Tetart; M Valette; N Viget; A Diarra; E Bontemps; G Corvaisier; M Brière; M De La Chapelle; M Gousseff; R Nguyen Van; M Thierry

Journal Article

Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With Human Immunodeficiency Virus: Outcomes in Real-world Setting With and Without Tenofovir Resistance

Makinson A
Bani-Sadr F
et al.

Clinical Infectious Diseases (2026)

DOI: 10.1093/cid/ciaf726

1Citations

2Readers

Get full text

Cite

CITATION STYLE

APA

Makinson, A., Bani-Sadr, F., Palich, R., Montès, B., Maillard, A., … Thierry, M. (2026). Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With Human Immunodeficiency Virus: Outcomes in Real-world Setting With and Without Tenofovir Resistance. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf726

Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With Human Immunodeficiency Virus: Outcomes in Real-world Setting With and Without Tenofovir Resistance

Cite

Register to see more suggestions